Shares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket trading Tuesday as the biotech company received ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach ...

In Vertex's most recent quarter, the company grew revenue at an 18% y/y pace to $170.4 million. This isn't bad: but we note that several points of Vertex's growth are stemming from recent ...

"If we do our jobs right, and you come back a year from now, this place is going to be a buzzing hive" -- Vertex Executive ...

Vertex Pharmaceuticals beat expectations for revenue but missed on earnings. The company has two recent FDA approvals and several treatments in late-stage trials. The core CF treatments make up ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...